Plain-English translation of NCT06581198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a personalized cell therapy for people with systemic lupus erythematosus (lupus) or lupus nephritis (a kidney complication of lupus) that hasn't improved with standard treatments. The medication works by collecting and reprogramming your own immune cells to help control the disease. Researchers want to see if this approach is safe and effective for people whose lupus hasn't responded to at least two other therapies.
Many people with lupus continue to struggle with active disease even after trying multiple standard medications, and their condition causes ongoing damage to organs and tissues. This trial exists to see whether this new cell-based treatment can help people for whom existing options haven't worked well enough.
If you qualify, you would receive the medication once after undergoing a preparation phase to reduce certain immune cells. This involves collecting your own immune cells, modifying them in a laboratory, and then returning them to your body. You would need to attend follow-up visits to monitor how you respond to the treatment and watch for any side effects. The study involves about 179 patients across multiple sites, and the research team will track your lupus activity and kidney function over time.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States